This site is intended only for healthcare professionals resident in Egypt
VyndamaxTM 61 mg (tafamidis) Abbreviated Prescribing Information:
DATE OF THIS DOCUMENT: 27-Oct-21
-Kindly report any violated online promotional ,educational and awareness material not having this message to the general administration for regulation of marketing and advertising materials at : www.edaegypt.gov.eg(link is external)
MOA: mechanism of action; MOD: mechanism of disease.
MOH Approval No. : HF0098OA171/082022
Invalidation Date : 11/08/2024
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
I confirm that I am a healthcare professional resident in Egypt.